Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia Therapy
Studies from Shanghai Jiao Tong University, Shanghai Institute of Hematology provide new data on acute myeloid leukemia therapy
April 13th, 2008
Fresh data on acute myeloid leukemia are presented in the report 'Acute promyelocytic leukemia: from highly fatal to highly curable.' "Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia. Morphologically, it is identified as the M3 subtype of acute myeloid leukemia by the French-American-British classification and cytogenetically is characterized by a balanced reciprocal translocation between chromosomes 15 and 17, which results in the fusion between promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARalpha)," scientists in Shanghai, People's Republic of China report. "It seems that the disease is the most malignant form...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-13)
|
